difficulties in Biological Technology
Navigation Links
difficulties in Biological Technology
Cornerstone Therapeutics Announces Closing of Chiesi Transaction
... to commercialize our products, including difficulties relating to the manufacture of Zyflo((R)) CR ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...... to commercialize our products, including difficulties relating to the manufacture of Zyflo CR(R) ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...
Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
... to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR tablets; ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
... to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R); our ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...Synthetech Announces Fiscal 2008 Results
... 2008 were disappointing. Production process difficulties reduced revenue and increased per unit costs, ... results. Management estimates that manufacturing difficulties related to certain customer projects reduced ... disappointed by the impact of specific production difficulties on financial results for the fourth quarter and ...Synthetech Reports First Quarter Fiscal 2010 Results
... lower than normal margins on certain products which encountered production difficulties in prior quarters; higher than average raw material costs on certain ... the timing and amount of shipments; the resolution of manufacturing difficulties and the benefit of production efficiencies or cost reductions; the impact ...... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...
NxStage Reports First Quarter 2009 Financial Results
... anticipated results, performance or achievements, including unanticipated difficulties in restructuring the payment terms of the Company's GE credit facility, ... products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in ...Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...Palomar and Q-MED AB Terminate International Distribution Agreement
... but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, ... the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party ...Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
... adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data ...... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...
... Sunstone" or the "Company"), today announced that due to the technical difficulties encountered on today's conference call, the company will hold a second ... will give callers the opportunity to ask questions since technical difficulties prevented the Company from addressing all questions on today's call. The ...
NeurogesX Reports Third Quarter 2008 Results
... and to carry out activities to commercialize NGX-4010, if approved; difficulties or delays in NeurogesX entering into commercialization partnerships ... without violating the intellectual property rights of others; other difficulties or delays in, clinical development, obtaining regulatory approval, market ...... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...... FDA, delay achieving or failure to achieve FDA approval of pegloticase, difficulties of expanding our product portfolio through in-licensing or acquisition; ... our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies ...
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing Millennium's products; government and ...Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY
... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...Palomar and Q-MED AB Enter Into International Distribution Agreement
... but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, ... the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party ...... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...Life Sciences Leader Joins Millennium Board of Directors
... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...Pressure BioSciences, Inc. Provides Corporate Update
... the possibility that the Company may encounter unforeseen technological difficulties in the development of the PCT technology, the possibility that the ... market as a needed improvement over current extraction methods, or other difficulties that would prevent or otherwise impair the Company's ability to install at ...NeurogesX Reports Second Quarter 2009 Results
... if approved, or the inability of physicians to obtain sufficient reimbursement for procedures associated with NeurogesX' products; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
... of GDC-0449, and Debiopharm may not be able to successfully advance CUDC-305 into clinical trials as planned. - Curis may experience difficulties or delays in obtaining or maintaining required regulatory approvals for products under development both internally and through its ...NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
... side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...ADVENTRX Pharmaceuticals Announces Financing
... Code; the risk that, if ADVENTRX liquidates its assets, the capital available for distribution to stockholders, if any, will be insignificant; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX-514, including validating commercial manufacturing ...NxStage Reports Second Quarter 2009 Financial Results
... performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory ...... including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the ...
... cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to ...
... to commercialization of Intermezzo ((R)); obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo ((R)); other difficulties or delays in the commercialization of Intermezzo ((R)), carrying out activities or obtaining payments under the Collaboration Agreement and clinical ...
... We bring process automation to clinical operations in the pharmaceutical, biotechnology and medical device industries. After encountering all the difficulties of implementing other leading clinical software programs, we realized that the cost of implementation and lost time for stakeholders to learn new ...
Bacteria pack their own demise
... forms they take while in action a difficult feat to pull off, requiring the simultaneous use of a whole range of different technologies. One of the difficulties for instance lay in the fact that part of the antitoxin lacks a fixed structure. This formlessness keeps it from being brought into view. Future ...NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
... indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...Other ContentspolydipsiapolyuriaporeporeporeporeporeporeporeporphyriaOther TagsAdolescentsWorriedEncephalitisEncephalitisOutpatientSunscreenCuredAnkleAnkleTrainedDentists
(Date:11/26/2009)...he bare essentials of life, the indispensable ingr...e on its own? Can we describe the molecular anatom... functions as a system? These are just some of the...n the European Molecular Biology Laboratory (EMBL)...io Genmica (CRG) in Barcelona, Spain, set out to a...
(Date:11/25/2009)...rs and ambulance workers faced a terrifying rescue...ttled to save people from the collapsing Twin Towe...uated as many people as they could in an area whic... their jobs even harder was the problem of poor co...es jammed mobile networks with calls and the emerg...
(Date:11/25/2009)...tal to your health as what you eat, found research...Their experiments in mice revealed that the daily ...erthe body,s metabolic clearinghouseis mostly cont...ian clock as conventional wisdom had it. , "If ...mber of genes completely independent of the circad...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3Flextronics Announces Expansion of Medical Disposables Offering 5645 1Flextronics Announces Expansion of Medical Disposables Offering 5645 2Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 1Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 2BioStorage Technologies Inc Accelerates European Expansion with Opening of New German Facility 5641 1BioStorage Technologies Inc Accelerates European Expansion with Opening of New German Facility 5641 2(Date:11/26/2009)...e/--Withcoldandfluseasonuponus,it,smoreimportantth...ectionsandavoidillness. ,, "Weneedtobeproactive...ngillnessifwe,resick,"saidEileenFinerty,RN,MS,CIC(...fectioncontrolandoccupationalhealthatHospitalforSp...cialSurgeryhasoneofthelowestinfectionratesofanyhos...
(Date:11/26/2009)...etrathiomolybdate (TM) has been shown in studies t... a disease caused by an overload of copper, and ce... little, however, is known about how the drug work...orthwestern University researchers now has provide...ure of TM bound to copper-loaded metallochaperones...
(Date:11/26/2009)...e letters from the North Pole, Textsanta.net lets ...m Santa , North Pole, AK ...ficiencies at the North Pole Santa Claus has added... the globe informed of his Christmas progress at t... department have identified a large and growing pe...
(Date:11/26/2009)... Communications announces a highly effective and u... struggling to make an economic recovery. , ...u fears is the type of challenge that could send a...ng to Dr. David Benton, business growth expert and...em – The Rfactor Intensive . “Fear ...
(Date:11/25/2009)...Newswire/--TheBartleHallConventionCenterwilltempor...10,whenKansasCityhoststhelatestinaseriesofmassivef...ceventhasthepotentialtobethebiggestoneyet,becausei...eekdaysinsteadofoveraweekend,"SheriWood,executived...oftheNationalAssociationofFreeClinics(NAFC). ,,...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[1] Research sheds light on workings of anti-cancer drug[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[1] Pharmacist Injects Cure for Ailing Businesses [1] Kansas City Prepares for Largest Free Health Clinic
AdolescentsWorriedArthiritisEncephalitisOutpatientAstrocytesSunscreenCuredAnkleTrainedScandalsCannabinoidsDentistsPolicemen
Other Tagsreflects 2reflects 3reflects 4reflects 5reflects 6reflects 7teacher 2teacher 3switching 2switching 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |